Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLF10 | Q13118 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27295914 | 0.83 | MCL1 (0.53) | MCL1ALDH1A1 | |
| SCHEMBL8770897 | 0.83 | MCL1 (0.38) | MCL1HTR3EHTR3BHTR1AHTR1D | |
| SCHEMBL8773468 | 0.79 | MAPT (0.39) | MCL1CYP1A2CYP2D6TSHRKDM4E | |
| SCHEMBL6036667 | 0.78 | MCL1 (0.35) | MCL1ALDH1A1HTR3EHTR3BHTR1A | |
| SCHEMBL8773287 | 0.78 | CA2 (0.38) | MCL1HTR7 | |
| SCHEMBL9013249 | 0.78 | MCL1 (0.35) | MCL1ALDH1A1HTR3EHTR3BHTR1A | |
| SCHEMBL8773382 | 0.78 | HSD17B10 (0.44) | TSHRKDM4EALDH1A1 | |
| SCHEMBL11240779 | 0.77 | GABRA1 (0.59) | MCL1KDM4EALDH1A1 | |
| SCHEMBL4925103 | 0.76 | MAOB (0.35) | MCL1HTR7 | |
| SCHEMBL16555880 | 0.76 | MCL1 (0.54) | MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582660-B2 | 2-thio-substituted imidazole derivatives and their use in pharmaceutics | C-A-I-R BIOSCIENCES GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-20060235054-A1 | 2-Thio-substituted imidazole derivatives and their use in pharmaceutics | MERCKLE-GMBH (DE) | 2006-10-19 | — | — | US | disclosed |
| EP-1539741-A1 | 2-THIO-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE IN PHARMACEUTICS | MERCKLE GMBH (DE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004018458-A1 | 2-THIO-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE IN PHARMACEUTICS | MERCKLE-GMBH (DE) | 2004-03-04 | — | — | WO | disclosed |
| EP-1112265-B1 | 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE | MERCKLE GMBH (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-6432988-B1 | RHEUMATIC DISEASES, (OSTEO)ARTHRITIS, CACHEXIA, INFLAMMATORY BOWEL DISEASE, TOXIC SHOCK SYNDROME, SEPSIS, CROHN*S DISEASE, PSORIASIS AND GOUT TREATMENT | MERCKLE GMBH (DE) | 2002-08-13 | — | — | US | disclosed |
| EP-1112265-A1 | 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE | MERCKLE GMBH (DE) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000017192-A1 | 2-ARYLALKYLTHIO -IMIDAZOLES, 2-ARYLALKENYL -THIO -IMIDAZOLES AND 2-ARYLALKINYL -THIO -IMIDAZOLES AS ANTI -INFLAMMATORY SUBSTANCES AND SUBSTANCES INHIBITING THE RELEASE OF CYTOKINE | MERCKLE GMBH (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235054-A1 | 2-Thio-substituted imidazole derivatives and their use in pharmaceutics | IL2, TPMT, IFNG | KLF10 4298/4885PKM 1486/4885MCL1 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.